Trial Profile

A randomized, placebo-controlled, double-blind Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R 835 Rigel Pharmaceuticals (Primary) ; Lipopolysaccharide
Indications Autoimmune disorders
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

Most Recent Events

06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
03 Jun 2020 According to a Rigel Pharmaceuticals media release, data from this study will be presented at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020.
03 Jun 2020 Results published in the Rigel Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com